Literature DB >> 14647466

Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors.

Junko Ueda1, Masahiro Kajita, Naoko Suenaga, Katsuyuki Fujii, Motoharu Seiki.   

Abstract

Membrane-type 1 matrix metalloproteinase (MT1-MMP/MMP-14) has been believed a key enzyme in tumor invasion, because it is expressed in a variety of malignant human tumors, and overexpression of the enzyme enhances the ability of cellular invasiveness. However, it has not necessarily been clarified whether the endogenously expressed MT1-MMP in human tumors plays a critical role in their invasiveness. We used RNA silencing technology to downregulate the endogenous MT1-MMP expression in human tumor cells (fibrosarcoma HT1080 and gastric carcinoma MKN-28 cell lines), and evaluated the effect on the invasion of a reconstituted basement membrane (Matrigel). Transfection of a double-stranded RNA targeted to the MT1-MMP gene decreased the level of the enzyme to less than 10-20% without affecting production of other MMPs. According to the degree of silencing, activation of proMMP-2 was inhibited. CD44 shedding was also inhibited, but only in part. Decreased MT1-MMP levels were also reflected in reduced cell motility on hyaluronan (HA) and invasion in Matrigel. Thus, specific downregulation of MT1-MMP expression was sufficient to cause significant inhibition of the migration and invasion of tumor cells, even though other MMPs continued to be expressed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14647466     DOI: 10.1038/sj.onc.1206962

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity.

Authors:  Lei Zhu; Fan Zhang; Ying Ma; Gang Liu; Kwangmeyung Kim; Xuexun Fang; Seulki Lee; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2011-11-01       Impact factor: 4.939

2.  Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.

Authors:  Anika Agarwal; Lidija Covic; Leila M Sevigny; Nicole C Kaneider; Katherine Lazarides; Gissou Azabdaftari; Sheida Sharifi; Athan Kuliopulos
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Self-organization of engineered epithelial tubules by differential cellular motility.

Authors:  Hidetoshi Mori; Nikolce Gjorevski; Jamie L Inman; Mina J Bissell; Celeste M Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-18       Impact factor: 11.205

4.  Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients.

Authors:  Subramanyam Dasari; Wudayagiri Rajendra; Lokanatha Valluru
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

5.  Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.

Authors:  Brenda L Petrella; Jouko Lohi; Constance E Brinckerhoff
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

6.  Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis.

Authors:  P L E M van Lent; P N Span; A W Sloetjes; T R D J Radstake; A W T van Lieshout; J J T M Heuvel; C G J Sweep; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2004-10-14       Impact factor: 19.103

7.  Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.

Authors:  Rajani Kaimal; Raid Aljumaily; Sarah L Tressel; Rutika V Pradhan; Lidija Covic; Athan Kuliopulos; Corrine Zarwan; Young B Kim; Sheida Sharifi; Anika Agarwal
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

Review 8.  Tumour endoproteases: the cutting edge of cancer drug delivery?

Authors:  J M Atkinson; C S Siller; J H Gill
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

9.  Peptide aptamers as new tools to modulate clathrin-mediated internalisation--inhibition of MT1-MMP internalisation.

Authors:  Rochana D Wickramasinghe; Paul Ko Ferrigno; Christian Roghi
Journal:  BMC Cell Biol       Date:  2010-07-23       Impact factor: 4.241

10.  Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts.

Authors:  Kirsten Riches; Michael E Morley; Neil A Turner; David J O'Regan; Stephen G Ball; Chris Peers; Karen E Porter
Journal:  J Mol Cell Cardiol       Date:  2009-06-11       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.